Team Kapital sources new funding for technology companies - in biotech, cleantech and IT. We typically source funds from Asian and North American investors – a market with huge enthusiasm for the innovation sector – but also have access to the usual VC suspects across Europe. We focus primarily on growth capital but are well known for our innovative work sourcing non-dilutive funding from China too. 

Latest Articles

New Chinese funding source is open for business

New Chinese funding source is open for business

Dynasty Biotechnology is pleased to announce commencement of a major partnership with Cambridge-based Nuformix in a long term, multi-pro...

Read More

Better Startups? Bring back the Grand Tour

Better Startups? Bring back the Grand Tour

The great country houses of Britain are full of beautiful art from other countries, but the UK’s great technology clusters have to paint t...

Read More

Live with passion

Live with passion

So I managed to fit in a single day's skiing last Sunday. Nothing very remarkable about that, you might think, until you learn that I haven...

Read More

Ready, Fire, Aim: pharma’s diagnosis-free growth strategy

Ready, Fire, Aim: pharma’s diagnosis-free growth strategy

So the global pharma and biotech industry still has a pipeline problem: cost per new drug is sky rocketing, volume of new approvals continue...

Read More


“Success means getting up just one more time than you fall down”–FortunePick Europe  #LessonLearned

“There is no idea that can't be improved upon: never settle, always evolve”–Michael Parks, Pick360  #LessonLearned

“Don't be afraid of failure but celebrate it and know what not to do next time”–Jeremy Rudolph, Palo Alto   #LessonLearned